Citation: J. Thambyrajah et al., A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patientswith coronary artery disease, J AM COL C, 37(7), 2001, pp. 1858-1863
Authors:
Landray, MJ
Thambyrajah, J
McGlynn, FJ
Jones, HJ
Baigent, C
Kendall, MJ
Townend, JN
Wheeler, DC
Citation: Mj. Landray et al., Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment, AM J KIDNEY, 38(3), 2001, pp. 537-546
Authors:
Holdaas, H
Jardine, AG
Wheeler, DC
Brekke, IB
Conlon, PJ
Fellstrom, B
Hammad, A
Holme, I
Isoniemi, H
Moore, R
Rowe, PA
Sweny, P
Talbot, DA
Wadstrom, J
Ostraat, O
Citation: H. Holdaas et al., Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial, KIDNEY INT, 60(5), 2001, pp. 1990-1997
Citation: C. Baigent et Dc. Wheeler, Should we reduce blood cholesterol to prevent cardiovascular disease amongpatients with chronic renal failure?, NEPH DIAL T, 15(8), 2000, pp. 1118-1119
Citation: Dc. Wheeler et J. Steiger, Evolution and etiology of cardiovascular diseases in renal transplant recipients, TRANSPLANT, 70(11), 2000, pp. SS41-SS45
Citation: J. Thambyrajah et al., Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?, CIRCULATION, 102(8), 2000, pp. 871-875
Citation: Dc. Wheeler, Ischaemic heart disease after renal transplantation: how to assess and minimize the risk, NEPH DIAL T, 14(5), 1999, pp. 1075-1077